医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
29期
106-107
,共2页
替加环素%比阿培南%鲍曼不动杆菌
替加環素%比阿培南%鮑曼不動桿菌
체가배소%비아배남%포만불동간균
biapenem%tigecycline%hospital-acquired pneumonia%Acinetobacter baumanni
目的：观察替加环素联合比阿培南治疗广泛耐药鲍曼不动杆菌肺部感染的临床疗效及安全性。方法分析2013年1月-2014年8月在我院呼吸内科住院期间肺部感染广泛耐药鲍曼不动杆菌患者采取替加环素联合比阿培南抗感染治疗的疗效和安全性。结果肺部广泛耐药鲍曼不动杆菌感染患者共14例，均为医院获得性肺部感染，替加环素联合比阿培南抗感染治疗时间7-21天，8例痊愈，2例好转，4例无效死亡。其中3例出现不良反应，经对症处理均好转。结论替加环素联合比阿培南治疗广泛耐药鲍曼不动杆菌效果较好。
目的：觀察替加環素聯閤比阿培南治療廣汎耐藥鮑曼不動桿菌肺部感染的臨床療效及安全性。方法分析2013年1月-2014年8月在我院呼吸內科住院期間肺部感染廣汎耐藥鮑曼不動桿菌患者採取替加環素聯閤比阿培南抗感染治療的療效和安全性。結果肺部廣汎耐藥鮑曼不動桿菌感染患者共14例，均為醫院穫得性肺部感染，替加環素聯閤比阿培南抗感染治療時間7-21天，8例痊愈，2例好轉，4例無效死亡。其中3例齣現不良反應，經對癥處理均好轉。結論替加環素聯閤比阿培南治療廣汎耐藥鮑曼不動桿菌效果較好。
목적：관찰체가배소연합비아배남치료엄범내약포만불동간균폐부감염적림상료효급안전성。방법분석2013년1월-2014년8월재아원호흡내과주원기간폐부감염엄범내약포만불동간균환자채취체가배소연합비아배남항감염치료적료효화안전성。결과폐부엄범내약포만불동간균감염환자공14례，균위의원획득성폐부감염，체가배소연합비아배남항감염치료시간7-21천，8례전유，2례호전，4례무효사망。기중3례출현불량반응，경대증처리균호전。결론체가배소연합비아배남치료엄범내약포만불동간균효과교호。
AIM To know the efficacy and safety of combination of biapenem and tigecycline for hospital-acquired pneumonia(HAP) caused by extensively drug resistant Acinetobacter baumanni(XDRAB).METHODS The clinical data of HAP patients caused by XDRAB from Jan ,2013 to AUG 2014 were analysed retrospectively, including therapeutic process,treatment outcome and adverse drug reactions. RESULTS Al the 14 patients with HAP treated with biapenem and tigecycline for 7-21 days. Eight patents were cured,2 got marked effects,and 4 died.The over effective rate was 83%.The symptoms were relatively light and could be aleviated by symptomatic treatment. CONCLUSION Biapenem combined with tigecycline is effective and safe in treatment of HAP caused by XDRAB.
